Alternative immunomodulators

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 3, 2003, Pages 245-248

  Forbes, Alastair ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Eicosanoid; ICAM 1; Interferon; Interleukin; Mycophenolate; Natalizumab; NF kappa B; Tacrolimus; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIBODY; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; DACLIZUMAB; FISH OIL; ICOSANOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 2; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID; NATALIZUMAB; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SHORT CHAIN FATTY ACID; TACROLIMUS; TRANSCRIPTION FACTOR; VERAPAMIL;

CLINICAL TRIAL; CROHN DISEASE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENTERITIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; TREMOR; WITHDRAWAL SYNDROME;

BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 0037338866     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200303000-00006     Document Type: Review

References (36)

1. Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5:239-245. First substantial report on use of tacrolimus in inflammatory bowel disease: apparently valuable, but uncontrolled data.
2. Bousvaros A, Kirschner BS, Werlin SL, Parker-Hartigan L, Daum F, Freeman KB, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatrics 2000; 137:794-799.
3. Ierardi E, Principi M, Rendina A, et al. Oral tacrolimus long term therapy in Crohn's disease with steroid resistance or dependence. Gut 1999; 46 (suppl V):A287.
4. Fellermann K, Herrlinger KR, Witthoeft T, Holmann N, Ludwig D, Stange EF. Tacrolimus (FK506): a new immunosuppressant for steroid refractory inflammatory bowel disease. Gastroenterology 2000; 118 (suppl 2):A786.
5. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001; 96:782-787.
6. Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, et al. Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate. Gastroenterol Clin Biol 2002; 26:17-22.
7. Wenzl HH, Hinterleitner TA, Fickert P, Aichbichler BW, Metzler O, Petritsch W. Low efficacy of long-term mycophenolate mofetil in patients with Crohn's disease. Gastroenterology 2000; 118 (suppl 2):A790.
8. Skelly MM, Curtis H, Jenkins D, Hawkey CJ. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Gastroenterology 2000; 118 (suppl 2):A789.
9. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol 1998; 93;2529-2532.
10. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999; 44:625-628. First controlled data on mycophenolate in inflammatory bowel disease. Apparent benefit in speed of onset compared to azathioprine but unblinded study.
11. Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114:433-440.
12. Stenson WF, Cort D, Rodgers J, Burakoff R, DeSchryver-Kecskemeti K, Gramlich TL, Beeken W. Dietary supplementation with fish oil in ulcerative colitis. Ann Int Med 1992; 87:609-614.
13. Hawthorne AB, Daneshmend TK, Hawkey CJ, Belluzzi A, Everitt SJ, Holmes GK, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992; 33:922-928.
14. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996; 334:1557-1560. Adequately powered study showing clear benefit for this preparation.
15. Senagore A, MacKeigan J, Scheider M, Ebrom S. Short chain fatty acid enemas: a cost effective alternative in the treatment of nonspecific proctosigmoiditis. Dis Colon Rectum 1992; 36:923-927.
16. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Guglio E, Frieri G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000; 45:976-981. Positive pilot study indicating added benefit over 5-ASA alone.
17. Hawkey CJ, Dube LM, Rountree LV, Linnen P J, Lancaster JF. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. Gastroenterology 1997; 112:718-724. Zileuton found ineffective.
18. Lichtenstein G. Medical therapies for inflammatory bowel disease. Curr Opin Gastroenterol 1993; 9:588-599.
19. 4 release by rectal mucosa in active ulcerative colitis. Aliment Pharmacol Ther 1992; 6:163-168.
20. Hawkey C, Rampton D. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease or treatment? Gastroenterology 1985; 89:1462-1488.
21. Rampton D, Collins C. Review article: thromboxanes in inflammatory bowel disease - pathogenic and therapeutic implications. Aliment Pharmacol Ther 1993; 7:357-367.
22. Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin-10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113:383-389. IL-10 a moderately effective agent in this pilot study.
23. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473-1482. IL-10 safe and well-tolerated, with clear advantage over placebo.
24. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:56-64.
25. Madsen SM, Schlichting P, Davidsen B, Nielsen OH, Federspiel B, Riis P, Munkholm P. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001; 96:1807-1815.
26. Debinski H, Forbes A, Kamm MA. Low dose interferon gamma for refractory Crohn's disease. Ital J Gastroenterol Hepatol 1997; 29:403-406.
27. Levin S, Fischer S, Christie D, Haggitt R, Ochs H. Intravenous immunoglobulin therapy for active extensive and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992; 87:91-100.
28. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol 1989; 11:136-138.
29. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, et al. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology 1994; 107:357-361.
30. Sawada K, Ohnishi K, Kosaka T, Chikano S, Yokota Y, Egashira A, et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Ther Apheresis 1997; 1:207-211.
31. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ. CD4 antibody treatment in patients with active Crohn's disease; a phase 1 dose finding study. Gut 1997; 40:320-327.
32. Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51:30-36. Negative study but safety of approach confirmed.
33. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121:268-274. Promising results from this pilot study of single dose therapy.
34. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289:1352-1354. Fascinating new approach with potential for use in humans.
35. Jensen MR, Dalum I, Steinaa L, et al. Immunization against TNFα - a new approach for the treatment of inflammatory bowel disease. Gastroenterology 2000; 118:A873. Unpublished work of great potential interest.
36. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nature Biotech 2000; 17:666-669. Provides the background to the work in Reference 35.